Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
María Agustina Perusini(University Health Network), Dennis Dong Hwan Kim(University Health Network), Anežka Kvetková(Masaryk University), Chang MyungHee(Princess Margaret Cancer Centre), Zhaolei Zhang(University of Toronto), Mark D. Minden(University Health Network), Ivana Ježíšková(Masaryk University), Kátia Bórgia Barbosa Pagnano(Universidade Estadual de Campinas (UNICAMP)), Jiřı́ Mayer(Masaryk University), José‐Mario Capo‐Chichi(University Health Network), Daniela Žáčková(Masaryk University), Jessie J.F. Medeiros(Ontario Institute for Cancer Research), Andrea Arruda(University Health Network), Kyoung Ha Kim(Soonchunhyang University Hospital Seoul), Tae‐Hyung Kim(Memorial Sloan Kettering Cancer Center), Hyewon Lee(Princess Margaret Cancer Centre), Jaeyoon Kim(LG (United States)), Carolina Pavlovsky(Unknown), Youngseok Yoo(Princess Margaret Cancer Centre), Tomáš Jurček(Masaryk University), Seongyoon Yi(Princess Margaret Cancer Centre), Sagi Abelson(Ontario Institute for Cancer Research)
Cited by 14
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k